
    
      PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are stratified by type
      of infection.

      Patients are randomly assigned to oral thalidomide or placebo. Therapy is administered daily
      for up to 8 weeks, beginning the night before antitubercular treatment is initiated.
    
  